

### About

NantKwest (Nasdaq: NK), is a pioneering, next generation, clinicalstage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body's first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or

NantKwest's unique NK cell based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to Induce cell death against cancer or infected cells by three different modes of action:

- (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact,
- (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and
- (3) Target-activated killing using the taNK\* platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells

Our aNK, haNK® and taNK™ platform addresses certain limitations of T-cell theraples including the reduction of risk of serious "cytokine storms," As an "off-the-shelf" therapy, NantKwest's NK cells do not rely on a patient's own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, Nantkwest's NK cells has been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care.



### Technology

### OVERVIEW - A Next Generation Immunotherapy Platform

### The Natural Killer Cell

The Immune system is a tapeatry of diverse families of Immune cells each with its own distinct role in protecting from intections and diseases. Among these immune cells are the natural killer, or NK, cells as the body's first line of defense. NK cells have the innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or activation by other support molecules. In contrast to adaptive immune cells such as T-cells, NK cells are imiquely powerful in that they are always activated to attack diseased cells, without a delay in killing. Our proprietary activated Natural Killer (aNK) platform is based upon highly potent Natural Killer cells from a unique cell line, harnessing the power of the innate immune system.









NantKwest's unique NK cell based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action:

# UNIQUE PLATFORM - MULTIPLE APPROACHES TO TARGETED KILLING







taNK

### alNK: Activated Natural Killer

Direct killing using NK-92 derived activated NK cells (aNK) that release toxic granules directly into the cancer cells through cell-to-cell contact.

### hank\*

Antibody-mediated killing using haNKs, which are aNK cells engineered to incorporate a high affinity recentor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody.

Target-activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.


## taNK™

### taNK\*



### ADMINISTRATION:

tank" sells are administrated to a patient and allocate unit they lateract with cancer colls



### ACTIVATION:

ISINAT CORN (CONCINCO CURRO) DORI Stress Rigarials Brough surface. Hippinosod Chimetoc Amper Bongtons (CARN) Hoding to cytolytic guaruulas. popularing toward the colf interface and the rollouse of cytolytics that recruit. additional immune colfs.



### DEGRANULATION:

Cytorytic gramities degranulate and dhicharde perfortes and granzymes into cancer cell.



### KILLING:

Cancer cell is wheat this to produce of the cell medicine and rucfast. Environment, DNA degradation, chumistic condensation, retochoodist (septimization, and reductive copyoni

### READ MORE

Chimeric antigen receptor (CAR) technology is among the most novel cancer therapy approaches currently in development. CARs are proteins that allow immune effector cells to target cancer cells displaying specific surface antigens.

taNK (target-activated Natural Killer) is a platform in which our aNK cells are engineered with one or more CARs to target proteins found on cancers and is then integrated with a wide spectrum of CARs. This strategy has multiple advantages over other CAR approaches using patient or donor sourced effector cells such as autologous T-cells, especially in terms of scalability, quality control and consistency.

Our most advanced laNK cell line expresses a CAR for ErbB2 (also known as HER2), a protein commonly found on breast, ovary, gastric, biadder and glioblastoma (brain) cancers. Other taNK programs are in various stages of development.

Play Video

HER2 taNK specifically targets and kills Her2 expressing cancer cell

Play Vide

HER2.taNK sertally kills Her2 expressing cancer cells

Contact us for information on NaniKwest's Living Drugs in a Bag® therapy considermentswest care

© 2017 NardKwest. All Rights Reserved. A member of the NardWorks occsystem of companies!





